Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Strong Sell at Zacks Research

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

Several other research analysts also recently commented on the company. Wall Street Zen upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Wedbush lifted their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 26th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and seven have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.81.

Sarepta Therapeutics Stock Up 2.1%

NASDAQ:SRPT opened at $20.21 on Tuesday. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -21.05, a price-to-earnings-growth ratio of 0.21 and a beta of 0.21. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $25.32. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $17.80 and a 200-day simple moving average of $19.29.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.15 million. During the same period in the prior year, the firm earned ($3.42) EPS. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Analysts anticipate that Sarepta Therapeutics will post 3.95 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the last quarter. Allworth Financial LP boosted its position in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,256 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.